We estimated adherence by calculating the PDC for each drug class prescribed to each patient from the index date to the end of our assessment period (December 31, 2006) using 2 different methods that differ in how the denominator of the adherence measure is calculated (
Sulfonylurea Compounds
These compounds work by stimulating the release of insulin from the pancreas, helping to lower blood glucose levels.
PubCompare.ai's AI-driven platform allows researchers to explore the latest literature, preprints, and patents related to sulfonylurea compounds, enhancing the reproducibility and accuracy of their studies.
Utilize the platform's AI comparisons to optimize your research workflow and uncover the best protocols for your work.
Discover new insights and advance your understanding of this important class of diabetes therapeutics.
Most cited protocols related to «Sulfonylurea Compounds»
Acetolactate synthase (ALS) is a key enzyme in the biosynthesis of the branched-chain amino acids leucine, isoleucine, and valine. Sulfonylurea herbicides, e.g. CS, bind reversibly to the ALS-FAD-thiamine pyrophosphate-Mg2+-decarboxylated pyruvate complex and also compete for the second pyruvate binding site in ALS [29 (link)]. Mutagenesis at these sites in ALS confers tolerance to sulfonylurea herbicides. For example, mALSs containing mutations at P197H, R198S, and W574L conferred resistance to CS in Arabidopsis [30 (link)]. To generate a CS-resistance marker gene for use in M. polymorpha, its ALS sequence was mutagenized to contain corresponding mutations (P207S/R208S/W582L) to those described above, as follows. First, M. polymorpha ALS cDNA was amplified by RT-PCR with the primer set ALS-P1 and ALS-P2 using first-strand cDNA synthesized from a 10-day-old thallus. The resultant ALS cDNA was cloned into the pENTR/D-TOPO vector (Life Technologies, Gaithersburg, MD, USA). A point mutation at W582L in the ALS sequence was introduced by PCR-based site-directed mutagenesis with the primer pair ALS-W582L-F and ALS-W582L-R, using the ALS cDNA plasmid as the template. The PCR product was digested with DpnI, and the digested PCR product was transformed into Escherichia coli competent cells (DH5α). The mutation in ALS was confirmed by sequencing the resultant plasmid. The mALS was prepared by repeating the same procedure with the primer set ALS-P207S-R208S-F and ALS-P207S-R208S-F using the W582L-mutated ALS as a template. The mALS cDNA was cloned into pCAMBIA1300 to replace the hpt gene, generating the plasmid pCAMBIA1300-mALS.
The marker cassettes pro35S×2:hpt:ter35S, pro35S×2:aacC1:ter35S, pro35S×2:mALS:ter35S, and pro35S×2:nptII:ter35S were prepared by PCR with the primer set Marker_LinF and Marker_RinF using pCAMBIA1300, pPZP221, pCAMBIA1300-mALS, and pCAMBIA2301, respectively, as the template. The marker cassettes were cloned into EcoRI-digested pGWB400 [31 (link)] using an In-Fusion HD cloning kit (Clontech, Mountain View, CA, USA) to replace the proNOS:nptII:terNOS cassette, generating pMpGWB100, pMpGWB200, pMpGWB300, and pMpGWB400, respectively. The E. coli DH5α cells harboring these plasmids were selected on LB medium containing 100 mg/l spectinomycin.
The Gateway-compatible binary vectors pMpGWBs were constructed using the same strategy as that used by Nakagawa et al. to construct pGWBs [31 (link),32 (link)]. Detailed procedures of pMpGWBs construction are described in
The vector for expression of TagRFP-LTI6b was constructed as follows: the GFP-LTI6b coding sequence was PCR-amplified using the primers GFP-LTI6b_GW_L1 and GFP-LTI6b_GW_R1 and cloned into pENTR/D-TOPO. The GFP coding sequence flanked by two NotI sites in this plasmid was replaced with the TagRFP-coding sequence with two similarly flanking NotI sites, which was PCR-amplified using the primers pENTRD_NotI_TagRFP_F and TagRFP_NotI_R. This plasmid was used for LR recombination with pMpGWB103 to generate pMpGWB103-TagRFP-LTI6b.
To construct the vector for expression of SP-GFP-HDEL, the SP-GFP-HDEL-coding sequence [33 ] was PCR-amplified using the primers SP_Lc and HDEL_R and cloned into pENTR/D-TOPO. The resulting vector was used for LR recombination with pMpGWB303 to generate pMpGWB303-SP-GFP-HDEL.
To construct the vectors for expression of tdTomato-NLS and GUS under the endogenous ELONGATION FACTOR1α promoter (proEF), the 1,729-bp promoter sequence of MpEF1α [34 (link)] was amplified by PCR using the primers MpEF-P_L1 and MpEF-P_R1 and cloned into pENTR/D-TOPO. The resulting vector was used for LR recombination with pMpGWB216 and pMpGWB404 to generate pMpGWB216-proEF and pMpGWB404-proEF, respectively.
Protocol full text hidden due to copyright restrictions
Open the protocol to access the free full text link
Participants who completed period I then entered period II, during which those randomised to canagliflozin (100 or 300 mg) or sitagliptin 100 mg continued on those treatments while those randomised to placebo switched to sitagliptin 100 mg in a blinded fashion. During the double-blind treatment period, glycaemic rescue therapy with glimepiride (added to study drug and background metformin) was initiated if FPG >15.0 mmol/l after day 1 to week 6, >13.3 mmol/l after week 6 to week 12, and >11.1 mmol/l after week 12 to week 26. Glimepiride therapy was also started if HbA1c >8.0% (64 mmol/mol) after week 26.
Most recents protocols related to «Sulfonylurea Compounds»
Propensity scores were estimated using a logistic regression that modelled the probability of initiating SGLT2i (exposure) versus a non-gliflozin medication (control) conditional on the baseline covariates. These propensity scores were then used to estimate stabilized inverse probability of treatment weights (IPTW) to account for imbalances in patient characteristics [24 (link)].
Study design for placebo-controlled trials included in the meta-analysis
Parameters | AWARD-1 | AWARD-5 | AWARD-8 | AWARD-10 | AWARD-11 | Ferdinand et al |
---|---|---|---|---|---|---|
Phase | Phase III | Phase II/III | Phase III | Phase III | Phase III | Phase II |
Randomization | Randomized | Randomized | Randomized | Randomized | Randomized | Randomized |
Blinding | Blinding | Double-blind | Double-blind | Double-blind | Double-blind | Double-blind |
Primary Endpoint | A1c | A1c | A1c | A1c | A1c | 24-h SBP |
Study Treatment Period | 52 weeks | 24 months | 24 weeks | 24 weeks | 52 weeks | 26 weeks |
Last scheduled visit with PBO | 26 weeks | 6 months | 24 weeks | 24 weeks | 52 weeks (no PBO) | 26 weeks |
Background therapy (Add-ons) | Met + TZD | Met mono | SU mono | SGLT2i with or without metformin | Met mono | Stable OAM |
Key inclusion/ exclusion criteria | ||||||
Age | ≥ 18 years | 18–75 years | ≥ 18 years | ≥ 18 years | ≥ 18 years | ≥ 18 years |
T2D duration | NA | ≥ 6 months | NA | NA | for ≥ 6 months | NA |
A1c | 7.0–11.0 | 7.0–9.5 | 7.5–9.5 | 7.0–9.5 | 7.5–11 | 7–9.5 |
BMI | 23–45 | 25–40 | ≤ 45 | ≤ 45 | ≥ 25 | NA |
Medication | Stable OAM | Diet & exercise / metformin and/or other OAM | Stable SU | SGLT2i with or without metformin for ≥ 3 months | Stable metformin for ≥ 3 months | OAM |
BMI body mass index, NA not applicable for the study’s design, Met metformin, mono monotherapy, OAM oral antihyperglycemic medication, PBO placebo, SBP systolic blood pressure, SGLT2i sodium-glucose cotransporter-2 inhibitors, SU sulfonylurea, T2D type 2 diabetes, TZD thiazolidinediones
This study was approved by the Institutional Ethics Review Boards of Osaka University Hospital and Sumitomo Hospital and was carried out in accordance with the principles of the Declaration of Helsinki. The study was announced to the public on the websites of our department at Osaka University Hospital and Sumitomo Hospital, and all patients were allowed to participate or refuse to participate in the study.
Three of these disproportionality scores, based on 2 × 2 disproportionality analysis, are well-established and currently used worldwide by several organisations for routine safety surveillance, i.e:
i) The Reporting Odds Ratio (ROR), defined as the ratio of the odds of the occurrence of therapy failure with antidiabetic drugs versus the occurrence of therapy failure without antidiabetic agents (van Manen et al., 2007 (link));
ii) The Proportional Reporting Ratio (PRR), comparing the frequency of occurrence of therapy failure in reports referring to antidiabetic agents with the frequency of occurrence of reports of therapy failure in reports that do not mention antidiabetic agents. (van Manen et al., 2007 (link)).
iii) The Empirical Bayesian Geometric Mean (EBGM) calculated using the Multi-item Gamma Poisson Shrinker (MGPS) Algorithm, using Bayesian shrinkage to improve the reliability of the disproportionality score (DuMouchel, 1999 (link)). We generated both the point estimates (EBGM) and their associated 90% confidence intervals labelled EB05–EB95.
iv) The Regression-enhanced Empirical Bayesian Geometric Mean (ERAM) calculated using the Regression-Adjusted Gamma Poisson Shrinker (RGPS) Algorithm (DuMouchel and Harpaz, 2012 ). We generated the point estimates (ERAM) and their associated 90% confidentiality intervals labelled ER05–ER95.
i) The upper limit of the 90% confidence interval (CI) of the ROR for cases (ROR95) is less than one;
ii) The PRR score is less than one and the corresponding p-value is less than 0.05;
iii) The upper limit of the 90% confidence interval of the EBGM for cases (EB95) is less than one;
iv) The upper limit of the 90% confidence interval of the ERAM for cases (ER95) is less than one.
Top products related to «Sulfonylurea Compounds»
More about "Sulfonylurea Compounds"
These drugs, also known as sulfonylureaa, work by stimulating the release of insulin from the pancreas, helping to lower blood glucose levels.
Researchers can utilize PubCompare.ai's AI-driven platform to explore the latest literature, preprints, and patents related to sulfonylurea compounds, enhancing the reproducibility and accuracy of their studies.
The platform's AI comparisons can help optimize the research workflow and uncover the best protocols for investigating this important class of diabetes therapeutics.
This includes discovering new insights and advancing the understanding of sulfonylureaa and their mechanisms of action.
Researchers may also find it useful to consider related terms and technologies, such as SAS version 9.4, SAS 9.4, SPSS version 18.0, AU5800 Platform, Hygromycin, Lantus, Bacterial genomic DNA extraction kits, Teneligliptin, Sitagliptin, and the Synchron DX600 analyzer.
These tools and compounds can provide additional context and capabilities for studying sulfonylureaa and their applications in diabetes management.
By leveraging the power of PubCompare.ai's AI platform and incorporating a holistic understanding of the sulfonylurea compound landscape, researchers can enhance the reproducibility, accuracy, and impact of their work in this critical area of diabetes research and treatment.